WuXi STA breaks ground for second manufacturing facility in US

This biopharmaceutical facility is one most significant private sector investment ever in the Middletown region

QPharma launches Ti OrderPoint 2

OrderPoint was designed as an advanced DTR solution from its first release in 2016.

Tavneos recommended by England’s NICE for the treatment of AAV

The decision follows authorization from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) in May 2022.

FDA accepts submission of olaparib in combination with abiraterone and prednisone for prostate cancer

First PARP inhibitor to demonstrate clinical benefit in radiographic progression-free survival in combination with a new hormonal agent with or without homologous recombination repair gene mutations

ResMed Q4 revenue up 4%; operating profit up 6%

The card-to-cloud device was launched into the U.S. and many other markets and is designed to work without an embedded communications module.

Enhertu approved in the US as the first HER2-directed therapy for patients with previously treated HER2-mutant metastatic non-small cell lung cancer

Based on DESTINY-Lung02 results which showed AstraZeneca and Daiichi Sankyo’s Enhertu reported a confirmed objective response rate of 57.7% in patients with HER2-mutant disease

We must be careful in adopting global technological practices, says Union Health Secretary

Urged stakeholders to come up with similar digital platforms and create homegrown best practices where Indian methods and Indian solutions dominate the digital spaces

GL Chemtech partners with Edgewater Capital to accelerate growth

Investment in response to increased demand for North American-based chemistry services

Apollo Hospitals posts Q1 FY23 consolidated PAT at Rs. 317.11 Cr

Apollo Hospital Group completed the acquisition of a hospital asset in Gurugram for a consideration of around Rs 450 crore.

Kaléo announces appointments and new government business unit